Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Edesa Biotech ( (EDSA) ) has issued an announcement.
On September 30, 2025, Edesa Biotech amended its agreement with the Government of Canada to shift its clinical focus for the experimental drug EB05 from Covid-19 induced ARDS to general ARDS. This amendment extends the project completion date to December 31, 2028, and adjusts the repayment schedule, reflecting strategic changes to benefit from a U.S. government-funded study, potentially impacting the company’s operational timeline and financial planning.
The most recent analyst rating on (EDSA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Edesa Biotech stock, see the EDSA Stock Forecast page.
Spark’s Take on EDSA Stock
According to Spark, TipRanks’ AI Analyst, EDSA is a Underperform.
Edesa Biotech exhibits significant financial challenges, reflected in zero revenue and persistent losses, severely impacting its overall score. Technical indicators show a stable market position, but poor valuation metrics further weigh down the stock’s attractiveness. The lack of revenue and cash flow sustainability poses significant risks.
To see Spark’s full report on EDSA stock, click here.
More about Edesa Biotech
Edesa Biotech is a company operating in the biotechnology industry, focusing on developing innovative treatments for critical-care conditions. The company is particularly involved in creating experimental drugs, such as EB05, aimed at treating Acute Respiratory Distress Syndrome (ARDS) caused by infectious agents.
Average Trading Volume: 24,529
Technical Sentiment Signal: Sell
Current Market Cap: $17.24M
For an in-depth examination of EDSA stock, go to TipRanks’ Overview page.